Target intelligence / Profile preview

Influenza A virus matrix protein 2 proton channel (M2)

Target
M2
Molecular classification
Ion channel, Viral protein, Integral membrane protein, Proton transporter
01

Overview

The M2 proton channel is a small, homotetrameric integral membrane protein found in the viral envelope of the influenza A virus, with a closely related but sequence-divergent counterpart in influenza B[1][3][7]. It forms a highly selective, pH-activated proton channel responsible for transporting protons from acidified endosomes into the viral interior during cell entry, a process essential for viral uncoating and initiation of infection[1][3][7][9]. The channel is also involved in modulating pH in the trans-Golgi during viral maturation and facilitating virus particle release[1][7]. Structurally, the channel is formed by four transmembrane helices, with key residues such as histidine 37 acting as the proton sensor and tryptophan 41 as the gate[6][7][9]. The activity of the M2 channel is blocked by the adamantane drugs amantadine and rimantadine, but high rates of resistance (e.g., S31N mutation) have limited their use[7][10]. The M2 protein remains a validated antiviral drug target, especially in the development of next-generation inhibitors for influenza therapeutics.

Other names
M2 proton channelInfluenza A M2 protein (AM2)Influenza B M2 protein (BM2)M2 ion channel
02

Mechanism of action

Channel blockade (e.g., amantadine/rimantadine bind within the pore, blocking proton conductance) Inhibition of pH regulation within virion, thereby impeding viral uncoating and replication

03

Biological functions

Proton transport across viral envelopeRegulation of pH within the virion during cell entryModulation of pH in trans-Golgi compartment during viral maturationViral uncoating (release of viral ribonucleoprotein into cytoplasm)Facilitates virus budding and particle release
04

Disease associations

Infection (essential for influenza virus infectivity and propagation)
05

Safety considerations

Rapid emergence of drug-resistant viral strains (notably S31N mutation and others render amantadine and rimantadine ineffective)Off-target effects of inhibitors are generally low, but clinical use of these drugs is limited by resistance rather than direct toxicity
06

Interacting drugs

Amantadine

1 more in the full profile.

07

Biomarkers

Detection of M2 protein or specific mutations (e.g., S31N mutation) for resistance to amantadine/rimantadine in viral strains

Beyond the preview

Go deeper on Influenza A virus matrix protein 2 proton channel (M2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Influenza A virus matrix protein 2 proton channel (M2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call